In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen Pharmaceuticals Inc.

www.janssenpharmaceuticalsinc.com

Latest From Janssen Pharmaceuticals Inc.

Horizon Scores In Second Round Of Sjögren’s Trial A Month After Amgen Buyout

The company announced positive results in the second population of its Phase II study of dazodalibep in patients with Sj

Clinical Trials Inflammation

Should Obese Patients Be Included In Every Drug Development Program?

FDA officials question whether modeling tools can predict which drugs have different disposition in obese populations. They say physiologically-based pharmacokinetic data cannot be used as a surrogate for actual clinical trial data at this time.

Clinical Trials FDA

FDA’s Robyn Bent On The Evolution of Patient-Focused Drug Development

The director of the agency’s patient-focused drug development program talks about how the program has improved the development and evaluation of new drugs, initiatives underway, and plans to standardize and harmonize the process.

FDA Leadership

Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover

The US major has announced its biggest acquisition to date in the form of a takeover that should expand its rare disease franchise and stave off concerns about internal products facing biosimilar competition.

M & A Rare Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register